Page 6 - B Pfizer News Today

A Pfizer pill for COVID-19 reduced the risk of hospitalization or death by 89% compared to a placebo group, the company said Tuesday in final study results that are similar to initial findings. Pfizer also said its drug, Paxlovid, showed "robust antiviral activity" against the omicron variant in lab studies.

A two-dose Pfizer/BioNTech vaccination provides just 33% protection against infection by the omicron variant of the coronavirus, but 70% protection against hospitalization, according to a large-scale analysis in South Africa released Tuesday.

A Pfizer pill for COVID-19 reduced the risk of hospitalization or death by 89% compared to a placebo group, the company said Tuesday in final study results that are similar to initial findings. Pfizer also said its drug, Paxlovid, showed "robust antiviral activity" against the omicron variant in lab studies.

The U.S. is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer's vaccine.

The U.S. is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer's vaccine.

A booster dose of the Pfizer-BioNTech vaccine provides protection against omicron that is similar to a two-dose course against the original strain of the coronavirus, the companies said Wednesday based on preliminary lab studies.

A booster dose of the Pfizer-BioNTech vaccine provides protection against omicron that is similar to a two-dose course against the original strain of the coronavirus, the companies said Wednesday based on preliminary lab studies.

Omicron, the latest coronavirus variant with a Greek name, features a buffet of mutations suggesting it will spread faster, stiff-arm vaccines to some degree and bind tighter to human cells but scientists aren't hitting the panic button yet.

Omicron, the latest coronavirus variant with a Greek name, features a buffet of mutations suggesting it will spread faster, stiff-arm vaccines to some degree and bind tighter to human cells but scientists aren't hitting the panic button yet.

The European Union's drug regulator on Thursday authorized Pfizer's coronavirus vaccine for use on children from 5 to 11 years old, clearing the way for shots to be administered to millions of elementary school pupils amid a new wave of infections sweeping across the continent.